GlassScriptPhysician profile
Elizabeth Newman
NPI 1366647976
$4,471.14
in general payments reported to CMS, 2019-2025
15 companies · $451 in 2025
The $451 reported for 2025 was more than what a typical Optometrist provider received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,314 · 2020: $14.87 · 2021: $564 · 2022: $568 · 2023: $781 · 2024: $779 · 2025: $451.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,011.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,010.59 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $2,128.27 | 2019-2025 | Total30, Precision7, Precision 1 |
| Johnson & Johnson Vision Care, INC. | $638.30 | 2021-2025 | Acuvue |
| Coopervision INC. | $516.12 | 2022-2025 | Myday Contact Lens, Clariti Contact Lens |
| Bausch & Lomb Americas INC. | $294.04 | 2022-2025 | Infuse, Infuse Multifocal |
| Kala Pharmaceuticals, INC. | $262.78 | 2021-2022 | |
| Astellas Pharma Global Development | $158.75 | 2024 | Izervay |
| Novartis Pharmaceuticals Corporation | $109.59 | 2021-2023 | |
| Abbvie INC. | $92.39 | 2023 | |
| Biotissue Holdings INC. | $89.34 | 2021-2022 | |
| Dompe US, INC. | $51.56 | 2024 | Oxervate |
| Tarsus Pharmaceuticals, INC. | $47.20 | 2024-2025 | Xdemvy |
| Quidel Corporation | $27.28 | 2023 | |
| Oyster Point Pharma, INC. | $26.56 | 2022 | |
| Maculogix, INC. | $17.68 | 2019 | |
| Allergan, INC. | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Newman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.